VERU - Veru Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6400
+0.0400 (+2.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.6000
Open1.6100
Bid1.6100 x 900
Ask1.6500 x 800
Day's Range1.6000 - 1.6600
52 Week Range1.1800 - 2.3700
Volume87,888
Avg. Volume158,709
Market Cap102.967M
Beta (3Y Monthly)0.43
PE Ratio (TTM)N/A
EPS (TTM)-0.3760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2014-04-28
1y Target Est6.38
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results

    -- Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising –-- Strong Financial Results for Q2 and YTD FY 2019 ---- Company to Host Investor.

  • GlobeNewswire11 days ago

    Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals, today announced that on Wednesday, May 15, 2019, the Company will report financial results for its fiscal 2019 second quarter ended March 31, 2019, before the market opens.  Veru’s management will host a conference call that same day at 8 a.m. Eastern Time to review the Company’s performance and to answer questions. Interested investors may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call. In addition, investors may access a replay of the conference call the same day beginning at approximately noon Eastern Time by dialing 877-344-7529 for US callers, or 412-317-0088 from outside the U.S., passcode 10130716.  The replay will be available for one week, after which, the recording will be available via the company’s website at https://verupharma.com/investors.

  • Veru (VERU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks18 days ago

    Veru (VERU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    Veru (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Introducing Veru (NASDAQ:VERU), The Stock That Tanked 81%
    Simply Wall St.last month

    Introducing Veru (NASDAQ:VERU), The Stock That Tanked 81%

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't w...

  • GlobeNewswire2 months ago

    Veru to Participate in Two Investor Conferences in March

    Barclays Global Healthcare Conference on March 12–14, 2019 at the Loews Miami Beach Hotel.  Veru will meet with investors.  There will be no webcast. Oppenheimer 29th Annual Healthcare Conference.  Veru will present at 10:20 a.m. ET on Wednesday, March 20, 2019 at the Westin New York Grand Central, in New York City. Veru Inc. is an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals.  The Veru prostate cancer pipeline includes zuclomiphene citrate (also known as VERU-944, cis-clomiphene) and VERU-111 (bisindole).  Zuclomiphene citrate is an estrogen receptor agonist being evaluated in a Phase 2 trial to treat hot flashes, a common side effect caused by hormone treatment for men with advanced prostate cancer.

  • Have Insiders Been Buying Veru Inc. (NASDAQ:VERU) Shares This Year?
    Simply Wall St.2 months ago

    Have Insiders Been Buying Veru Inc. (NASDAQ:VERU) Shares This Year?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examplesRead More...

  • GlobeNewswire3 months ago

    Veru Reports Strong Fiscal 2019 First Quarter Financial Results

    -- Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling -- -- Company to Host Investor.

  • GlobeNewswire3 months ago

    Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced that four presentations relating to Veru drug candidates are being given at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium being held February 14-16, 2019 at the Moscone West Building in San Francisco, California. Three of the presentations will be about VERU-111, our first-in-class selective oral alpha and beta tubulin inhibitor, which is in a Phase1b/Phase 2 clinical study in 5 clinical sites in the United States.  The Phase 1b/2 addresses the large and growing unmet medical need to provide therapies for men who have metastatic castration resistant prostate cancer and who have also become resistant to novel androgen blocking agents (enzalutamide or abiraterone).  There are currently no FDA approved drugs approved for this indication.

  • Earnings Preview: Veru (VERU) Q1 Earnings Expected to Decline
    Zacks3 months ago

    Earnings Preview: Veru (VERU) Q1 Earnings Expected to Decline

    Veru (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced that on Wednesday, February 13, 2019, the Company will report financial results for its fiscal 2019 first quarter ended December 31, 2018, before the market opens.  Veru’s management will host a conference call that same day at 8 am Eastern Time to review the Company’s performance and to answer questions. Interested investors may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call. In addition, investors may access a replay of the conference call the same day beginning at approximately noon Eastern Time by dialing 877-344-7529 for U.S. callers, or 412-317-0088 from outside the U.S., passcode 10128045.  The replay will be available for one week, after which, the recording will be available via the company’s website at https://verupharma.com/investors.

  • GlobeNewswire4 months ago

    Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company, today announced that it has initiated and enrolled the first patient in a clinical trial of its proprietary, next generation prostate cancer drug, VERU-111. The open-label Phase 1b/2 clinical trial for VERU-111, a novel oral drug, will be evaluated in men with metastatic refractory prostate cancer that would be given prior to intravenous chemotherapy. “Upon successful completion of this important clinical trial, we will move forward with additional clinical studies including a pivotal Phase 3 trial,” commented Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru.

  • Before You Buy Veru Inc. (NASDAQ:VERU), Consider Its Volatility
    Simply Wall St.4 months ago

    Before You Buy Veru Inc. (NASDAQ:VERU), Consider Its Volatility

    If you're interested in Veru Inc. (NASDAQ:VERU), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...

  • GlobeNewswire4 months ago

    Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019

    Three of the presentations will be for VERU-111, the Company’s proprietary, next generation, first-in-class selective oral tubulin inhibitor for the treatment of advanced prostate cancer which is enrolling in a Phase1b/2 clinical study, and the fourth presentation will be for zuclomiphene citrate (VERU-944), a proprietary oral estrogen receptor agonist drug for the treatment of hot flashes caused by androgen deprivation therapy (ADT) for men with advanced prostate cancer which is currently enrolling in a Phase 2 clinical trial. Additional information on the meeting can be found on the ASCO Genitourinary Cancers Symposium website: https://gucasym.org/.

  • GlobeNewswire4 months ago

    Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary Tadalafil and Finasteride Combination tablet met the U.S. Food and Drug Administration’s (FDA) requirements for bioavailability and bioequivalence for the co-administration of tadalafil 5mg and finasteride 5mg dosed daily for benign prostatic hyperplasia (BPH) (Tad-Fin Combination Tablet).

  • GlobeNewswire5 months ago

    Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter

    -- Advancing Multiple Drug Candidates, Two Drugs Currently in Clinical Trials, Company Transforming into Biopharmaceutical with Focus on Prostate Cancer, Successfully Completes.

  • GlobeNewswire5 months ago

    Veru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company, today announced that on Thursday, December 13, 2018, the company will report financial results for the fourth quarter and fiscal year ended September 30, 2018, before the market opens.  Veru management will host a conference call that same day at 8 a.m. Eastern Time to review the company’s performance and to answer questions. Interested investors may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call. In addition, investors may access a replay of the conference call the same day beginning at approximately noon Eastern Time by dialing 877-344-7529 for US callers, or 412-317-0088 from outside the U.S., passcode 10126693.  The replay will be available for one week, after which, the recording will be available via the company’s website at https://verupharma.com/investors.

  • What Kind Of Shareholders Own Veru Inc (NASDAQ:VERU)?
    Simply Wall St.5 months ago

    What Kind Of Shareholders Own Veru Inc (NASDAQ:VERU)?

    A look at the shareholders of Veru Inc (NASDAQ:VERU) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders Read More...

  • GlobeNewswire5 months ago

    Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil – Finasteride Tablet for Benign Prostatic Hyperplasia

    -- Combination Tablet Treats BPH Symptoms; Shrinks Prostate and Prevents BPH Progression -- -- NDA Submission Target Mid 2019 -- MIAMI, Dec. 03, 2018 -- Veru Inc. (NASDAQ:.

  • GlobeNewswire6 months ago

    Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for VERU-111 (bisindole), a first-in-class, next generation, proprietary, oral tubulin inhibitor for the treatment of refractory metastatic prostate cancer. The Company plans to conduct an open label Phase 1b/2 clinical trial in men with metastatic castration resistant prostate cancer that have also become resistant to, or who have failed to respond to, abiraterone or enzalutamide.